Publicaciones en colaboración con investigadores/as de Radboud University Nijmegen Medical Centre (4)

2022

  1. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies

    European Journal of Haematology, Vol. 109, Núm. 3, pp. 205-214

2021

  1. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

    European Journal of Haematology, Vol. 106, Núm. 3, pp. 389-397

2020

  1. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

    PLoS ONE, Vol. 15, Núm. 9 September

2019

  1. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study

    Blood, Vol. 133, Núm. 6, pp. 540-549